TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37464390

Group type: EXPERIMENTAL
Intervention: Visual cueing using laser shoes
Number of subjects: 10
Study: 37464404

Group type: EXPERIMENTAL
Intervention: Dextrain Manipulandum™ training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 42
Study: 37464448

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol (ERP) implementation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Center-specific implementation report card
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Engagement with center-specific implementation teams
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rapid-cycle feedback approach
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mixed-method evaluation approach
Number of subjects: 18
Study: 37464551

Group type: EXPERIMENTAL
Intervention: Liberty 640PM (EPS 2.0)
Number of subjects: 41
Study: 37464862

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 739
Study: 37464978

Group type: EXPERIMENTAL
Intervention: SHR0302 8 mg once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warfarin 5 mg (CYP2C9)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Omeprazole 20 mg (CYP2C19)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Midazolam 15 mg (CYP3A4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Repaglinide 0.5 mg (CYP2C8)
Number of subjects: 24
Study: 37465323

Group type: EXPERIMENTAL
Intervention: Oral roflumilast 500 μg once daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 37465396

Group type: EXPERIMENTAL
Intervention: PK-guided prophylaxis with rurioctocog alfa pegol targeting FVIII trough of 8-12%
Number of subjects: 0
Study: 37465817

Group type: EXPERIMENTAL
Intervention: BI 1291583 1 mg once daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BI 1291583 2.5 mg once daily
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BI 1291583 5 mg once daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 240
Study: 37465907

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 42
Study: 37465924

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 37465959

Group type: EXPERIMENTAL
Intervention: Dual-task Augmented Reality Treatment (DART)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional Dual-task Training (DTT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: DART
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional DTT
Number of subjects: 47
Study: 37465966

Group type: EXPERIMENTAL
Intervention: Wolff-Parkinson-White (WPW) pattern in neonates
Number of subjects: 17489

Group type: COMPARATOR
Intervention: Control group (matched 1:4 to WPW cases)
Number of subjects: 17489
Study: 37465991

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (MMAF-containing monoclonal antibody-drug conjugate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin dosing regimens
Number of subjects: 0
Study: 37466000

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g over 10 minutes followed by 1 g over 8 hours
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 37466018

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NME) combined with back-care counseling
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NME)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combined intervention (NME + counseling)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control
Number of subjects: 219
Study: 37466110

Group type: EXPERIMENTAL
Intervention: Preoperative ondansetron (4 mg in 100 ml of 0.9% saline 1 hour before induction of anaesthesia)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intraoperative ondansetron (4 mg in 100 ml of 0.9% saline 30 min before end of surgery)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Preoperative ondansetron
Number of subjects: 121

Group type: COMPARATOR
Intervention: Intraoperative ondansetron
Number of subjects: 121
Study: 37466151

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (benazepril 10 mg or trandolapril 2 mg)
Number of subjects: 9379

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (losartan 50 mg)
Number of subjects: 9379
Study: 37466213

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 37466221

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted A/Hong Kong/125/2017 (H7N9) MIV
Number of subjects: 304

Group type: COMPARATOR
Intervention: Unadjuvanted A/Hong Kong/125/2017 (H7N9) MIV
Number of subjects: 304
Study: 37466280

Group type: EXPERIMENTAL
Intervention: MIND diet with mild caloric restriction
Number of subjects: 604

Group type: COMPARATOR
Intervention: Control diet with mild caloric restriction
Number of subjects: 604
Study: 37466374

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37466379

Group type: EXPERIMENTAL
Intervention: In-clinic cervicovestibular rehabilitation program (education, home exercises, manual techniques, sub-symptom threshold aerobic exercise [STAE] program)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Telerehabilitation program (education, home-exercises, STAE program without manual techniques)
Number of subjects: 41
Study: 37466456

Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention during venipuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group) during venipuncture
Number of subjects: 0
Study: 37466566

Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy with paclitaxel associated with systemic chemotherapy
Number of subjects: 30
Study: 37466690

Group type: EXPERIMENTAL
Intervention: Bilateral LI4 acupuncture prior to IUD insertion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 72
Study: 37466938

Group type: EXPERIMENTAL
Intervention: Videos with Black speakers
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Videos with physician presenters
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Videos about prostate cancer screening
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Videos with patient presenters
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Videos about clinical trials
Number of subjects: 2904

Group type: EXPERIMENTAL
Intervention: Videos with Black presenters
Number of subjects: 2904
Study: 37466951

Group type: COMPARATOR
Intervention: Non-MGD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate MGD
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Severe MGD
Number of subjects: 69
Study: 37466983

Group type: EXPERIMENTAL
Intervention: CXA-UP
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 200
Study: 37467018

Group type: EXPERIMENTAL
Intervention: Intervention to reduce bioaerosol exposure (specific details not provided)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Health examinations and questionnaires (specific details not provided)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Laboratory analyses (specific details not provided)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Statistical analysis (specific details not provided)
Number of subjects: 673
Study: 37467030

Group type: EXPERIMENTAL
Intervention: UM171-expanded CB
Number of subjects: 137
Study: 37467119

Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 14

Group type: COMPARATOR
Intervention: FVIII products
Number of subjects: 14

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 14
Study: 37467180

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Rifaximin plus non-absorbable disaccharide
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Non-absorbable disaccharides
Number of subjects: 4545
Study: 37467213

Group type: COMPARATOR
Intervention: Lumicitabine (single loading dose then 9 maintenance doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumicitabine (40/20 mg/kg, 60/40 mg/kg LD/MD twice-daily for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37467227

Group type: EXPERIMENTAL
Intervention: Intervention group (potassium rich diets, potassium supplements, and mineralocorticoid receptor antagonists (MRA) for six months)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 37467243

Group type: EXPERIMENTAL
Intervention: Bilateral Personal Sound Amplification Products (PSAPs)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No PSAPs (Control)
Number of subjects: 28
Study: 37467318

Group type: EXPERIMENTAL
Intervention: GDA-201 (NK cells expanded ex vivo with IL-15 and NAM) combined with rituximab
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GDA-201 (NK cells expanded ex vivo with IL-15 and NAM)
Number of subjects: 19
Study: 37467348

Group type: EXPERIMENTAL
Intervention: Modified bonding technique with an additional layer of compomer adhesive at the molar/tube interface.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional bonding technique.
Number of subjects: 30
Study: 37467452

Group type: EXPERIMENTAL
Intervention: Olaparib and temozolomide
Number of subjects: 22
Study: 37467454

Group type: EXPERIMENTAL
Intervention: Clinician nudge
Number of subjects: 2146

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Patient only nudge
Number of subjects: 2146

Group type: EXPERIMENTAL
Intervention: Patient and clinician nudge
Number of subjects: 2146
Study: 37467458

Group type: EXPERIMENTAL
Intervention: Multi-cancer detection test using a targeted methylation assay and machine learning classifiers
Number of subjects: 3508

Group type: EXPERIMENTAL
Intervention: Multi-cancer detection test
Number of subjects: 3508
Study: 37467497

Group type: EXPERIMENTAL
Intervention: GBS6 vaccine (various formulations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GBS6 vaccine (most immunogenic formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naturally acquired anti-CPS IgG
Number of subjects: 0
Study: 37467498

Group type: EXPERIMENTAL
Intervention: Zilebesiran (10, 25, 50, 100, 200, 400, or 800 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Zilebesiran (≥200 mg)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Zilebesiran (800 mg) under high-salt diet conditions
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Zilebesiran (800 mg) coadministered with irbesartan
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 37467628

Group type: EXPERIMENTAL
Intervention: Digital preoperative screening (n=200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Face-to-face screening (n=201)
Number of subjects: 400
Study: 37467930

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg q3w; 16 cycles)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Atezolizumab (in stage II-IIIA PD-L1 TC ≥1%)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Atezolizumab (in stage II-IIIA PD-L1 TC ≥50%)
Number of subjects: 1005
Study: 37467936

Group type: EXPERIMENTAL
Intervention: Physio-EndEA
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control
Number of subjects: 31
Study: 37468045

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (56 days at levels 1.2 to 2.6 times the Recommended Dietary Allowance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinol isotope dilution (RID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model-predicted TBS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy peers (control group)
Number of subjects: 0
Study: 37468185

Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 1641

Group type: EXPERIMENTAL
Intervention: Incomplete Revascularization (ICR)
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Conservative management (CON)
Number of subjects: 1641
Study: 37468217

Group type: EXPERIMENTAL
Intervention: Non-standard inhaler names
Number of subjects: 1150
Study: 37468530

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37468570

Group type: EXPERIMENTAL
Intervention: Risk-model group (FIT + risk factors including age, sex, smoking status, and CRC family history)
Number of subjects: 22748

Group type: COMPARATOR
Intervention: FIT-only group
Number of subjects: 22748
Study: 37468569

Group type: EXPERIMENTAL
Intervention: Palbociclib (first-line treatment)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Palbociclib (de novo MBC)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Palbociclib (≥ second-line treatment)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Palbociclib (overall cohort)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Palbociclib (adverse events)
Number of subjects: 191
Study: 37468652

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) navigation system
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard CT-guided bone biopsy (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both groups (AR and Control)
Number of subjects: 8
Study: 37468685

Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 3225
Study: 37468751

Group type: EXPERIMENTAL
Intervention: Open Total Gastrectomy (OTG)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Minimally Invasive Total Gastrectomy (MITG)
Number of subjects: 96
Study: 37468836

Group type: EXPERIMENTAL
Intervention: High genetic risk score (GRS) (≥ 3)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Low genetic risk score (GRS) (0-2)
Number of subjects: 192
Study: 37468859

Group type: EXPERIMENTAL
Intervention: RFID localization technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hook wire localization (gold-standard)
Number of subjects: 40
Study: 37468890

Group type: EXPERIMENTAL
Intervention: North Star Ambulatory Assessment (NSAA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Health Utilities Index (HUI3)
Number of subjects: 61
Study: 37468898

Group type: EXPERIMENTAL
Intervention: Parent coaching via telerehabilitation (video conferencing)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care (in-clinic parent coaching)
Number of subjects: 200
Study: 37468918

Group type: EXPERIMENTAL
Intervention: Human umbilical cord blood-MSCs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 37468932

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall predictive cut-off value
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: <5% reduction in PANSS total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: <10% decrease in PANSS total score
Number of subjects: 0
Study: 37468978

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE) combined with Cognitive Behaviour Therapy (CBT) for 15 weeks of PE and 10 weeks of CBT
Number of subjects: 4
Study: 37468987

Group type: EXPERIMENTAL
Intervention: Real-Time Delphi (RTD)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Multi-Round Delphi (MRD)
Number of subjects: 222
Study: 37469099

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37469291

Group type: EXPERIMENTAL
Intervention: Achieving recompensation after alcohol abstinence
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Alcohol abstinence
Number of subjects: 204
Study: 37469757

Group type: EXPERIMENTAL
Intervention: Self-learning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peer-learning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Peer-learning with expert feedback
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 37470057

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy and anti-PD-L1 (atezolizumab)
Number of subjects: 50
Study: 37470101

Group type: EXPERIMENTAL
Intervention: Mitiperstat 2.5 mg
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg
Number of subjects: 660

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study: 37470137

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus Vorinostat (DL1: 100 mg, DL2: 200 mg)
Number of subjects: 52
Study: 37470295

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg every 8 weeks (q8w)
Number of subjects: 2992

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg every 8 weeks (q8w)
Number of subjects: 2992

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg q8w
Number of subjects: 2992
Study: 37470379

Group type: EXPERIMENTAL
Intervention: nCT
Number of subjects: 2211

Group type: EXPERIMENTAL
Intervention: nCRT
Number of subjects: 2211
Study: 37470445

Group type: EXPERIMENTAL
Intervention: Intravenous remdesivir (200 mg followed by 100 mg daily for 5 days)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No study drug (control)
Number of subjects: 131
Study: 37470678

Group type: EXPERIMENTAL
Intervention: Tailored music listening; details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not available
Number of subjects: 0
Study: 37470718

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (≥3 daily insulin injections/insulin pump therapy)
Number of subjects: 1441
Study: 37470772

Group type: EXPERIMENTAL
Intervention: Prediction model based on age, waist circumference, systolic blood pressure, glycated hemoglobin, antihypertensive medication use, and early onset preeclampsia (yes/no)
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: Conventional predictors used in the prediction model
Number of subjects: 1397
Study: 37470840

Group type: EXPERIMENTAL
Intervention: Accelerated bilateral theta-burst stimulation (TBS) consisting of 5 sequential bilateral intermittent TBS (600 pulses) and continuous TBS (600 pulses) daily for 5 days at 120% resting motor threshold.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Accelerated bilateral theta-burst stimulation (TBS)
Number of subjects: 25
Study: 37470901

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 99

Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All groups (warm water, decaffeinated coffee, caffeinated coffee)
Number of subjects: 99
Study: 37470969

Group type: EXPERIMENTAL
Intervention: SMILE surgery using the 500-kHz Visumax laser platform
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Preoperative ORA
Number of subjects: 444
Study: 37471052

Group type: EXPERIMENTAL
Intervention: CMV+ infants (n = 29, 12%)
Number of subjects: 249

Group type: COMPARATOR
Intervention: CMV- infants
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: CMV+ infants
Number of subjects: 249
Study: 37471089

Group type: EXPERIMENTAL
Intervention: Multidomain intervention with exercise, cognitive training, and vitamin D (arm 1)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Exercise, cognitive training, and placebo vitamin D (arm 2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Exercise, sham cognitive training, and vitamin D (arm 3)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Exercise, sham cognitive training, and placebo vitamin D (arm 4)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group with balance-toning exercise, sham cognitive training, and placebo vitamin D (arm 5)
Number of subjects: 175
Study: 37471115

Group type: EXPERIMENTAL
Intervention: wMammogram intervention (mobile web app)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (educational brochure)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: wMammogram intervention
Number of subjects: 122
Study: 37471117

Group type: EXPERIMENTAL
Intervention: Polybactum (PLGG) administered for 3 cycles followed by a 1-month follow-up period without treatment.
Number of subjects: 55
Study: 37471122

Group type: EXPERIMENTAL
Intervention: CBT-I delivered via Noctem COAST and CPP-led deprescribing
Number of subjects: 50
Study: 37471135

Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced standard care (control)
Number of subjects: 200
Study: 37471145

Group type: EXPERIMENTAL
Intervention: HDL-SPE
Number of subjects: 340
Study: 37471280

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent (RES) system
Number of subjects: 50
Study: 37471452

Group type: EXPERIMENTAL
Intervention: Monitoring electrodes replaced every 12 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Monitoring electrodes replaced every 24 hours
Number of subjects: 66
Study: 37471574

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection followed by adjuvant treatment (standard arm)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Sentinel lymph node biopsy only (experimental arm)
Number of subjects: 218
Study: 37471590

Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg every 2 weeks for 16 weeks, followed by 12 weeks of sarilumab or placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: sarilumab 200 mg
Number of subjects: 15
Study: 37473602

Group type: EXPERIMENTAL
Intervention: Empowering education on nutrition impact side effects
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 83
Study: 37473746

Group type: EXPERIMENTAL
Intervention: Sucroferric Oxyhydroxide (SFOH) 1,500 mg iron/day
Number of subjects: 286

Group type: COMPARATOR
Intervention: Sevelamer Carbonate 2.4 g/day
Number of subjects: 286
Study: 37473848

Group type: EXPERIMENTAL
Intervention: ROSE postpartum depression prevention program
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Enhanced care as usual
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: ROSE program
Number of subjects: 2320